Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
Gane EJ, DeJesus E, Janczewska E, George J, Diago M, Da Silva MH, Reesink H, Nikitin I, Hinrichsen H, Bourgeois S, Ferenci P, Shukla U, Kalmeijer R, Lenz O, Fevery B, Corbett C, Beumont M, Jessner W. Gane EJ, et al. Among authors: hinrichsen h. BMC Infect Dis. 2017 Jun 2;17(1):389. doi: 10.1186/s12879-017-2444-3. BMC Infect Dis. 2017. PMID: 28577353 Free PMC article. Clinical Trial.
Expert opinion on the treatment of patients with chronic hepatitis C.
Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP. Zeuzem S, et al. Among authors: hinrichsen h. J Viral Hepat. 2009 Feb;16(2):75-90. doi: 10.1111/j.1365-2893.2008.01012.x. Epub 2008 Aug 28. J Viral Hepat. 2009. PMID: 18761607 Free PMC article. Review.
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, Buggisch P, Rössle M, Hinrichsen H, Merican I, Ilan Y, Mauss S, Abu-Mouch S, Horban A, Müller TH, Welsch C, Chen R, Faruqi R, Pedicone LD, Wedemeyer H. Manns M, et al. Among authors: hinrichsen h. J Hepatol. 2011 Sep;55(3):554-563. doi: 10.1016/j.jhep.2010.12.024. Epub 2011 Jan 13. J Hepatol. 2011. PMID: 21237227 Clinical Trial.
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S. Sarrazin C, et al. Among authors: hinrichsen h. Z Gastroenterol. 2012 Jan;50(1):57-72. doi: 10.1055/s-0031-1282015. Epub 2012 Jan 5. Z Gastroenterol. 2012. PMID: 22222799 Review. German.
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H; Hep-Net Acute HCV-III Study Group. Deterding K, et al. Among authors: hinrichsen h. Lancet Infect Dis. 2013 Jun;13(6):497-506. doi: 10.1016/S1473-3099(13)70059-8. Epub 2013 Mar 22. Lancet Infect Dis. 2013. PMID: 23523674 Clinical Trial.
169 results